We're going after that genetic difference that makes it cancer
From the quiet study of cave bacteria, a Utah biochemist has uncovered a molecular mechanism that may one day redefine how humanity confronts cancer — not by poisoning the body indiscriminately, but by reading the genetic language of disease and acting only where it is spoken. The discovery of Cas12a2 at Utah State University reminds us that the most consequential breakthroughs often begin not with a cure in mind, but with simple curiosity about how life defends itself. Medicine's oldest ambition — to heal one thing without harming another — now has a new and promising instrument.
- A CRISPR enzyme found in cave bacteria can distinguish cancer cells from healthy tissue by reading their internal genetic code, triggering a targeted destruction that traditional chemotherapy cannot achieve.
- The discovery upends a long-standing limitation in oncology: because cancer cells originate from our own bodies, they are nearly invisible to blunt-force treatments that damage healthy tissue as collateral.
- Early mouse model tests showed the system activating inside human cancer cells while remaining dormant in surrounding healthy tissue — a selectivity that researchers describe as both rare and significant.
- The path forward is cautious: the team must validate results against real patient tumor samples and collaborate with the Huntsman Cancer Institute before any human trials can even be considered.
- The research stands as a testament to the unpredictable value of foundational science — a study of how bacteria survive in caves quietly became a potential turning point in cancer treatment.
Ryan Jackson was studying cave bacteria when his team at Utah State University stumbled onto something extraordinary: a new CRISPR tool, called Cas12a2, that could kill cancer cells while leaving healthy tissue untouched — a goal medicine has pursued for decades.
CRISPR, derived from bacterial immune systems, allows scientists to design molecular navigators that locate and cut specific genetic sequences. Cas12a2 is a distinct enzyme that, when activated, doesn't make a single precise edit — it launches what Jackson describes as a "DNA shredding rampage," destroying the cell entirely. The key is how it decides when to act: it reads the internal RNA signature of a cell, springs into action if it detects cancer, and remains dormant in healthy tissue until it breaks down harmlessly.
In mouse models carrying human patient-derived cancer cells, the system worked with striking selectivity. This matters because cancer cells look like normal cells from the outside, which is why conventional chemotherapy struggles to spare healthy tissue. Cas12a2 doesn't rely on appearance — it reads what's inside.
Jackson is careful to temper the excitement. The mouse studies used lab-grown cell lines, not primary tumor samples, and human trials remain years away. His team is now collaborating with the Huntsman Cancer Institute to test the tool against actual patient tissue — the critical next step before any clinical path can be mapped.
The discovery began not as a cancer project but as basic research into how cave bacteria defend against viruses — the kind of foundational science whose value is rarely obvious in advance. For Jackson, whose own son lives with an autoimmune disease, the implications feel deeply personal. Medicine's holy grail, he says, is the ability to change one thing without harming everything else. For the first time, that goal feels closer.
Ryan Jackson was studying cave bacteria when he stumbled onto something that stopped him cold. The biochemistry associate professor at Utah State University and his team had discovered a new type of CRISPR tool—a molecular scissors derived from bacterial immune systems—that could do something medicine has chased for decades: kill cancer cells while leaving healthy tissue alone.
The tool is called Cas12a2, and it works by recognizing genetic signatures unique to cancer. Unlike chemotherapy, which poisons indiscriminately and damages healthy cells in the process, Cas12a2 reads the internal genetic code of a cell and decides whether to activate. If it detects the RNA signature of cancer, it springs into action, shredding the cell's DNA. If it finds normal tissue, it remains dormant and eventually breaks down. Jackson described the moment he understood what they'd found as euphoric—he felt, he said, like he was on drugs.
To understand why this matters, it helps to know what CRISPR actually is. The acronym stands for Clustered Regularly Interspaced Short Palindromic Repeats, a mouthful that describes a bacterial immune system. Bacteria use CRISPR to remember viruses they've encountered and fight them off if they return. Scientists realized in the early 2010s that they could repurpose this system as a precision tool for editing genes. They design a guide RNA—a molecular navigator—that matches a specific genetic sequence, pair it with a Cas protein like Cas9, and the two work together to find and cut DNA at exactly the right spot. Researchers can then add or delete genetic material, rewriting the code that makes up an organism.
Cas12a2 is a different kind of Cas enzyme, one that Jackson's team discovered in cave bacteria. When activated, it doesn't just make a single cut; it goes into what Jackson calls a "DNA shredding rampage," destroying the infected cell entirely. This is the mechanism that bacteria use to protect their colonies from viral invasion. Jackson and his colleagues realized it could be repurposed for cancer.
The team tested the idea in mice carrying human cancer cells derived directly from patients. They injected a Cas12a2 system designed to recognize the RNA signature of those specific cancer cells. When the system entered a cancer cell, it activated and killed it. When it entered surrounding healthy tissue, it stayed off. The selectivity worked. This is crucial because cancer arises from our own cells—they look like us from the outside, which is why traditional therapies struggle to distinguish them. Cas12a2 doesn't rely on appearance. It reads what's inside.
But Jackson is careful not to oversell what remains an early-stage discovery. The mouse studies used immortalized cell lines, cancer cells that have been grown in labs for years and are somewhat removed from the reality of human tumors. Before any human trials, his team must test Cas12a2 against primary tissue—actual cancer samples taken directly from patients. They're already collaborating with researchers at the Huntsman Cancer Institute at the University of Utah on this next phase. The path from laboratory success to clinical treatment is long, and there's no timeline for when, or if, this technology will reach patients.
Yet Jackson sees the larger significance. The discovery emerged from basic research into how cave bacteria defend themselves against viruses—work that, on its surface, might seem like an odd use of taxpayer money. But that foundational investigation led to a tool that could transform cancer treatment. Jackson's own son has an autoimmune disease, and the possibilities this opens feel personal. The holy grail of medicine, he says, is the ability to manipulate one thing without harming everything else. For the first time, Cas12a2 suggests that goal might be within reach.
Citas Notables
The immune system of cave bacteria holds the cure for cancer— Ryan Jackson, associate professor of biochemistry at USU
I felt like I was on drugs. I was high. It was just like, oh my gosh, this could selectively kill cancer cells— Ryan Jackson, describing his reaction to the discovery
La Conversación del Hearth Otra perspectiva de la historia
So this came from studying cave bacteria. How does that connection even happen?
Jackson's team didn't invent Cas12a2 from scratch. Someone else had already discovered it in cave bacteria as part of basic research into how those organisms fight viruses. Jackson's insight was recognizing that this bacterial immune weapon could be repurposed to target cancer. It's a reminder that breakthroughs often come from unexpected places.
The selectivity is the real breakthrough, isn't it? That it can tell the difference between cancer and healthy cells?
Exactly. Cancer cells look almost identical to healthy cells from the outside, which is why chemotherapy can't distinguish them and ends up poisoning both. Cas12a2 reads the internal genetic code—the RNA signature that's actually different in cancer. It's like the difference between judging someone by their appearance versus knowing their actual nature.
How far away are we from using this in people?
Years, at minimum. They've tested it in mice with human cancer cells, but that's controlled. They need to prove it works in real patient tumors, in living tissue. That work is already underway with collaborators at the University of Utah, but there's no timeline for human trials.
What did Jackson mean when he said he felt like he was on drugs?
He was describing the moment he realized what they'd discovered. The implications hit him all at once—a tool that could selectively kill cancer without the collateral damage of traditional therapy. For a scientist, that's the kind of moment that justifies years of unglamorous foundational research.
Is there a risk this gets overhyped?
Jackson himself is being measured about it. He calls it a potential cure, but he's also clear about what still needs to happen. The real risk is that people hear "cancer cure discovered" and expect treatments next year. The science is real, but the timeline is long.